CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the pulsatile release of endogenous growth hormone (GH) from the pituitary gland. It exists in two forms:
With DAC (Drug Affinity Complex): Binds to albumin, extending its half-life to about 8 days, allowing for weekly injections.
Without DAC: Also known as modified GRF (1-29) or Sermorelin analog, with a shorter half-life (~30–60 minutes), requiring daily or multiple daily injections.
It works by activating GHRH receptors, leading to increased GH and insulin-like growth factor-1 (IGF-1) levels. This can result in increased muscle mass, fat loss, improved recovery, and anti-aging effects.
CJC-1295 (with DAC) has been studied in clinical trials for growth hormone deficiency and HIV-associated lipodystrophy but is not FDA-approved for any indication. It is used off-label and in research settings, often in combination with growth hormone-releasing peptides (GHRPs) like Ipamorelin for synergistic effects.
Potential side effects include injection site reactions, joint pain, fluid retention, and elevated blood glucose.